Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Iovance Biotherapeutics (IOVA) over the last 4 years, with Dec 2024 value amounting to -$1.28.

  • Iovance Biotherapeutics' EPS (Weighted Average and Diluted) rose 2.94% to -$0.33 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.22, marking a year-over-year increase of 26.95%. This contributed to the annual value of -$1.28 for FY2024, which is 32.28% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported EPS (Weighted Average and Diluted) of -$1.28 as of FY2024, which was up 32.28% from -$1.89 recorded in FY2023.
  • Iovance Biotherapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$1.28 during FY2024, with a 5-year trough of -$2.49 in FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.89 (2023), whereas its average is -$1.89.
  • As far as peak fluctuations go, Iovance Biotherapeutics' EPS (Weighted Average and Diluted) decreased by 11.66% in 2022, and later skyrocketed by 32.28% in 2024.
  • Over the past 4 years, Iovance Biotherapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.23 in 2021, then declined by 11.66% to -$2.49 in 2022, then rose by 24.10% to -$1.89 in 2023, then spiked by 32.28% to -$1.28 in 2024.